Administer intravenously (slowly), intramuscularly, or subcutaneously. The IV route is preferred for rapid onset and controlled titration during acute hypotension.

Ephedrine acts directly on alpha and beta adrenergic receptors and indirectly by causing the release of noradrenaline from sympathetic neurons.

• •Hypersensitivity to ephedrine or any component of the formulation.
• •Narrow-angle glaucoma.
• •Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy.
• •Severe hypertension, severe coronary artery disease, or other cardiovascular diseases where increased blood pressure would be dangerous.
• •Thyrotoxicosis, pheochromocytoma.

Store at controlled room temperature (20-25°C), protect from light. Do not freeze.

Symptoms include tachycardia, hypertension, palpitations, headache, tremor, anxiety, seizures, and potentially coma. Management is symptomatic and supportive, which may include alpha-blockers for severe hypertension and benzodiazepines for seizures.

Pregnancy Category C. Use only if the potential benefit justifies the potential risk to the fetus. Excreted into breast milk; use with caution in breastfeeding mothers.